IL-1β blockade prevents cardiotoxicity and improves the efficacy of immune checkpoint blockers and chemotherapy against pancreatic cancer in mice with obesity
Our findings provide the rationale and compelling data to test a Food and Drug Administration-approved anti-IL-1β antibody in combination with chemotherapy and dual ICB therapy in patients with pancreatic cancer with obesity.
Authors
- Mikäel J. Pittet (ORCID: https://orcid.org/0000-0002-2060-4691)
- Heena Kumra (ORCID: https://orcid.org/0000-0001-7065-6716)
- Marie Siwicki (ORCID: https://orcid.org/0000-0001-6330-8780)
- Rakesh K. Jain (ORCID: https://orcid.org/0000-0001-7571-3548)
- Dai Fukumura (ORCID: https://orcid.org/0000-0002-9505-4444)
- Patrik L. Andersson (ORCID: https://orcid.org/0000-0002-2088-6756)
- Peigen Huang (ORCID: https://orcid.org/0000-0002-3184-6493)
- Dan G. Duda (ORCID: https://orcid.org/0000-0001-7065-8797)
- William W. Ho (ORCID: https://orcid.org/0000-0002-1272-8184)
- Igor L. Gomes‐Santos (ORCID: https://orcid.org/0000-0001-5946-8300)
- Nilesh P. Talele (ORCID: https://orcid.org/0000-0003-2758-8599)
Institutions
- University of Geneva (CH)
- Agency for Science, Technology and Research (SG)
- University of Calgary (CA)
- Singapore Immunology Network (SG)
- Massachusetts General Hospital (US)
- Ludwig Cancer Research (CH)
- Swiss Cancer Center Léman (CH)
- Center for Systems Biology (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1136/jitc-2024-011404
- Citations
- 4
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 4.18
Funders
- National Foundation for Cancer Research
- Ludwig Institute for Cancer Research
- National Institute of Mental Health
- National Cancer Institute
- National Institute of Neurological Disorders and Stroke